Table 3.

Reported clinical trials of second-generation, CD19-targeted CAR T cells for B-ALL

Reference	Site	n	Phase	CAR design	Median age (yr)	Conditioning chemotherapy	CAR dose	CR	MRD- negative	Bridge to allo-SCT	EFS	OS
[35]	MSKCC	16	1	19-28z	50	CTX	3 × 106/kg	88%	75%	44%	ND	ND
[38]	UPENN	30	1	19-BBz	14	Physician’s choice	0.8–21 × 106/kg	90%	79%	10%	67% at 6 mo	78% at 6 mo
[37]	NCI	21	1	19-28z	13	Flu 25 mg/m2 × 3 CTX 900 mg/m2	0.03–3 × 106/kg	67%	57%	48%	ND	51.6% at 10 mo